Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
SL-22P by Hebei Senlang Biotechnology for Refractory Brain Metastasis: Likelihood of Approval
SL-22P is under clinical development by Hebei Senlang Biotechnology and currently in Phase I for Refractory Brain Metastasis. According to...
SL-22P by Hebei Senlang Biotechnology for Solid Tumor: Likelihood of Approval
SL-22P is under clinical development by Hebei Senlang Biotechnology and currently in Phase I for Solid Tumor. According to GlobalData,...
SL-22P by Hebei Senlang Biotechnology for Liver Cancer: Likelihood of Approval
SL-22P is under clinical development by Hebei Senlang Biotechnology and currently in Phase I for Liver Cancer. According to GlobalData,...